MiMedx Group, Inc. announced on July 30, 2025, a strategic collaboration with Vaporox, Inc. to co-promote and co-market their wound care offerings. As part of the agreement, MiMedx made an investment in Vaporox and secured certain exclusivity rights related to potential acquisition discussions.
Vaporox is commercializing its patented Vaporous Hyperoxia Therapy (VHT) device, which delivers ultrasonic mist and concentrated oxygen for treating chronic and hard-to-heal wounds. The VHT device has received 510(k) clearance from the U.S. Food & Drug Administration for nine types of wounds, including Diabetic Foot Ulcers, Venous Leg Ulcers, and Pressure Ulcers.
Clinical studies have demonstrated VHT's ability to achieve wound healing rates exceeding 80% at 20 weeks when combined with standard wound care. MiMedx views this as a highly complementary addition that will help grow its presence in chronic wound care settings, with VHT showing promising efficacy as an adjunct therapy to MiMedx's advanced wound care products like EPIFIX.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.